CTOs on the Move

GreenwichBiosciences

www.greenwichbiosciences.com

 
Greenwich Biosciences is the leader in researching cannabinoid medicines for rare epilepsies like Dravet Syndrome, LGS, TSC, and others.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Virpax Pharmaceuticals

Virpax`s lead product candidate, Probudur, is being developed using our proprietary liposomal encapsulation to deliver a sustain release of local anesthetic at the wound/incision site to control post-operative pain for 96 hours. We have executed Cooperative Research and Development Agreements (CRADA), as well as the National Institute of Health/NCATS; U.S. Army Institute of Surgical Research/Department of Defense to develop differentiated non-addictive treatment options and the Epilepsy Therapy Screening Program (ETSP) which is focused on focused on addressing drug resistant epilepsy, disease prevention and modification. The three products in development are targeting unmet global needs in three separate multi-billion-dollar markets, including rare diseases. Our proprietary drug-delivery-platforms have been developed to optimize the efficacy of nonaddictive medications to manage Post Operative Pain, Severe Pain, Post Cancer Pain, PTSD, and Rare Pediatric Epilepsy including Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (Orphan Diseases)

Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to combat cancer. Checkmate`s product candidate, CMP-001, is an advanced generation TLR9 agonist delivered as a biologic virus-like particle designed to trigger the body`s innate immune system to attack tumors in combination with other therapies.

Bright Pharmaceutical Services

Bright Pharmaceutical Services is a Sherman Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Oryzon

Oryzon’s MISSION is to identify and manipulate biomarkers -genes and proteins- allowing the development of new therapeutic tools in the quest to improve human health – covering unmet clinical needs- and in benefits for our shareholders. Oryzon’s VISION is to become a world leader company in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.  

A Better Way

​A Better Way is a San Francisco Bay Area nonprofit that empowers children and families to develop the insights, life skills, and permanent relationships that promote their social, emotional, educational and economic well- being.